Here are five observations:
1. The company’s proposed tax-free spin-off of QiG Group will be called Nuvectra after the process is complete.
2. Nuvectra will be a neuromodulation medical device company initially focused on the development and commercialization of a neurostimulation technology platform.
3. Joseph A. Miller, Jr., PhD, has been named director and chairman of the board of Nuvectra. He served on Greatbatch’s board of directors but will step to take up his new role with Nuvectra.
4. Scott Drees has been named as Nuvectra’s CEO. He previously served as neuromodulation portfolio manager for QiG Group.
5. The spin-off is expected to be completed by the end of 2015. However, it is subject to a number of considerations including final approval of Greatbatch’s board of directors.
More articles on devices:
Medovex signs distribution agreement with Aureus Medical: 5 key facts
Blue Belt Technologies partners with Acibadem Healthcare Group for orthopedic surgical robotics center: 5 key points
LifeScience Alley appoints Sheri Dodd of Medtronic to board of directors: 4 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
